Curevo Vaccines
Latest round
- Series B
Last raised
- Mar 2025
Total raised
- $170M
Investors
- 9
About Curevo Vaccines
, trading under the name Curevo Vaccine, is a clinical-stage biotechnology company specializing in the development of non-mRNA vaccines for shingles and chickenpox. As of 2022, the company’s pipeline program includes CRV-101, a vaccine being investigated in phase 1 clinical study that can prevent shingles in older adults and chickenpox in immunocompromised youngsters.
Who invested in Curevo Vaccines
9 investors across 4 rounds
See all investors in Curevo Vaccines
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Curevo Vaccines
Who invested in Curevo Vaccines?
Curevo Vaccines has 9 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Curevo Vaccines raised?
Curevo Vaccines has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did Curevo Vaccines last raise money?
Curevo Vaccines's most recent round on record is a Series B, in Mar 2025.
What does Curevo Vaccines do?
, trading under the name Curevo Vaccine, is a clinical-stage biotechnology company specializing in the development of non-mRNA vaccines for shingles and chickenpox.
Where is Curevo Vaccines headquartered?
Curevo Vaccines is headquartered in Bothell, US.
Which VCs invest in companies like Curevo Vaccines?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biopolymers companies at Curevo Vaccines's stage. Their profiles are linked below.
VCs backing biopolymers startups at Series B
Raising like Curevo Vaccines? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.